Vanguard Total Stock Market ETF (VTI)

Baird upgraded Palantir to ‘Outperform’ from ‘Neutral’ while keeping its $200 price target unchanged.

SOFI shares traded up over 4% in pre-market on Tuesday after a relentless sell-off that lasted for seven straight sessions.

Jackson said he is “long” Palantir, pointing to the analytics company’s results as evidence of a marked shift in how easily it is now winning business.

The company projected its Q1 2026 revenue below analyst estimates, according to data from fiscal.ai.

It's more important than ever to ensure you're investing in the right places.

Atossa Therapeutics said last week that its board has approved a reverse stock split of the company’s common stock, at a ratio of 15:1, with an effective time of 12:01 a.m. Eastern Time on February 2, 2026.

Piper Sandler cited softer cryptocurrency trading volumes, the end of the football season weighing on prediction market revenue, and rising doubts about the momentum of retail trading as reasons for the downtrend.

FLXR is an actively managed ETF providing diversified exposure to global fixed income markets through a flexible, multi-sector approach.

AKRE is a concentrated ETF emphasizing high-quality U.S. equities and disciplined stock selection.

Explore how subtle differences in holdings and risk profiles could influence your choice between these two foundational ETFs.

The company reported revenue of $3.02 billion for the quarter, 25% higher compared to the same period last year, and above analyst estimates of $2.9 billion.

According to a report from Bloomberg, at least four of Apple’s AI researchers and one top Siri executive have quit the company in recent weeks.

China SXT Pharmaceuticals announced a 1-for-150 reverse share split, effective Feb. 3, 2026.

Barclays flagged ongoing supply constraints that continue to limit the potential upside in iPhone shipments.

Raymond James analyst Melissa Fairbanks upgraded Sandisk to ‘Outperform’ from ‘Market Perform’ rating, with a price target of $725.

The company announced that it has decided to cease clinical development of its lead asset dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP).

Due to certain macroeconomic conditions, it hasn't been a good stretch for this sector.

This energy services firm provides specialized fluids and water management solutions to oil and gas operators worldwide.